EVALUATION OF THE RENAL EXCRETION CHARACTERISTICS OF TC-99M MERCAPTOACETYLGLYCYL-D-ALANYLGLYCINE IN HEALTHY-VOLUNTEERS

被引:9
作者
BORMANS, GM [1 ]
CLEYNHEN, BJ [1 ]
DEROO, MJK [1 ]
VERBRUGGEN, AM [1 ]
机构
[1] CATHOLIC UNIV LEUVEN,HOSP GASTHUISBERG,DEPT NUCL MED,B-3000 LOUVAIN,BELGIUM
来源
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1992年 / 19卷 / 04期
关键词
TC-99M MERCAPTOACETYLGLYCYLALANYLGLYCINE-DA; TC-99M MERCAPTOACETYLTRIGLYCINE; MERCAPTOACETYLTRIPEPTIDES; RENAL TRACER AGENTS;
D O I
10.1007/BF00175141
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
During a study of C-methyl derivatives of technetium-99m mercaptoacetyltriglycine (Tc-99m-MAG3) it was found that the isomer of Tc-99m-mercaptoacetylglycyl-D-alanylglycine (Tc-99m-MAGAG-DA) is superior to Tc-99m-MAG3 with regard to its renal excretion characteristics in both mice and the baboon. We have now compared the renal handling of Tc-99m-MAGAG-DA and Tc-99m-MAG, in 6 healthy volunteers in a paired study. Renograms of Tc-99m-MAGAG-DA show a shorter time to renal maximum and a lower residual renal activity at 30 min post-injection (p.i.). The urinary excretion of Tc-99m-MAGAG-DA is higher at both 30 and 60 min p.i. The plasma concentration of Tc-99m-MAGAG-DA is lower than that of Tc-99m-MAG3 at each moment up to 60 min p.i., and the plasma clearance is accordingly higher. It is concluded that Tc-99m-MAGAG-DA is excreted more efficiently than Tc-99m-MAG3, but the preparation of Tc-99m-MAGAG-DA requires a HPLC purification step, and this limits its practical clinical usefulness.
引用
收藏
页码:271 / 277
页数:7
相关论文
共 22 条
[1]   COMPARISON OF TC-99M-MERCAPTOACETYLTRIGLYCINE AND I-131 ORTHOIODOHIPPURATE IN DETERMINATION OF EFFECTIVE RENAL PLASMA-FLOW (ERPF) [J].
ABDELDAYEM, HM ;
SADEK, S ;
ALBAHAR, R ;
SABHA, M ;
ELSAYED, M .
NUCLEAR MEDICINE COMMUNICATIONS, 1989, 10 (02) :99-107
[2]  
BORMANS G, 1990, NUCL MED BIOL, V17, P499
[3]  
BORMANS G, 1989, J NUCL MED ALLIED S, V33, P275
[4]  
BORMANS G, 1992, IN PRESS NUCL MED BI, V19
[5]  
BRANDAU W, 1988, APPL RADIAT ISOTOPES, V39, P121
[6]  
BUBECK B, 1988, NUCL MED BIOL, V15, P99
[7]  
BUBECK B, 1987, NUC COMPACT, V18, P260
[8]  
CLEYNHENS B, 1989, Journal of Labelled Compounds and Radiopharmaceuticals, V26, P41
[9]   A NEW CLASS OF OXOTECHNETIUM(5+) CHELATE COMPLEXES CONTAINING A TCON2S2 CORE [J].
DAVISON, A ;
JONES, AG ;
ORVIG, C ;
SOHN, M .
INORGANIC CHEMISTRY, 1981, 20 (06) :1629-1632
[10]  
DAVISON A, 1979, J NUCL MED, V20, pP641